Mission Statement, Vision, & Core Values of SciSparc Ltd. (SPRC)

A company's Mission Statement, Vision, and Core Values are the bedrock, especially for a clinical-stage pharmaceutical firm like SciSparc Ltd. (SPRC) whose success hinges on long-term drug development, not immediate revenue. You see the tension in the numbers: the company reported a $9.33 million Net Loss for the first half of 2025, but still managed a $1.46 million Net Income for the nine months ended September 30, 2025, showing a volatile but focused path.

How does a firm with a relatively small $3.89 million market capitalization as of November 2025 fund its work on complex central nervous system (CNS) disorders like Tourette syndrome and Alzheimer's disease agitation? Do their stated principles truly map to their strategic actions, like the recent transfer of their advanced clinical portfolio valued at $11.6 million? Let's unpack the core beliefs driving their cannabinoid-based drug pipeline.

SciSparc Ltd. (SPRC) Overview

You need to know where SciSparc Ltd. (SPRC) stands right now: it is a clinical-stage pharmaceutical company focused on developing novel, cannabinoid-based therapies for central nervous system disorders, and its financials show a mixed but improving picture with recent positive net income. The core business is drug development, but the company also maintains a small, revenue-generating online sales segment for hemp-based products.

SciSparc Ltd., incorporated in 2004 and headquartered in Tel Aviv, Israel, was formerly known as Therapix Biosciences Ltd. before changing its name in January 2021. The firm operates in the biotechnology industry, and its strategy centers on creating a portfolio of assets based on cannabinoid pharmaceuticals. This is defintely a high-risk, high-reward space, but the company has been active with strategic moves, like the October 2025 sale of its majority-owned subsidiary MitoCareX to N2off.

The company's product pipeline is what drives its long-term valuation, focusing on four main drug candidates in clinical trials. Here's the quick rundown on their core programs:

• SCI-110: Targets Tourette syndrome and Alzheimer's disease with agitation.
• SCI-210: For autism spectrum disorder (ASD) and status epilepticus.
• CannAmide: An anti-inflammatory and chronic pain solution.
• Hemp-based Products: Online sales of hemp seed oil capsules, gummies, and creams.

For the first half of 2025, the company reported sales of USD 0.461 million, which reflects the scale of its current commercial operations, largely from the hemp-based product segment. This is a clinical-stage company, so current sales are not the main story; pipeline progress is. You can dig deeper into the company's history, ownership, and how it makes money here: SciSparc Ltd. (SPRC): History, Ownership, Mission, How It Works & Makes Money.

2025 Financial Performance Highlights

The latest reports, covering up to the end of the third quarter of 2025, show a crucial shift in the company's bottom line, moving from a half-year loss to a nine-month net income. This is the kind of volatility you expect in clinical-stage biotech, but the third-quarter results are a positive sign.

For the six months ended June 30, 2025, SciSparc Ltd. reported a net loss of USD 9.33 million, which is a significant cash burn as the company pushes its drug candidates through clinical trials. However, the sales figure for that same half-year period was USD 0.461 million, which, while not 'record-breaking' (it was a drop from USD 0.84 million a year prior), still provides a baseline of commercial revenue from its non-pharmaceutical products.

The real highlight comes from the nine-month period ended September 30, 2025, where the company reported a net income of USD 1.46 million. This is a massive improvement from the net loss seen in the first half of the year and shows that strategic financial events-like asset sales or major accounting adjustments-are having a material impact. The third quarter alone contributed USD 0.5 million in net income. This is what matters: the company is demonstrating an ability to generate net positive results, even with a small market capitalization of USD 3.89 million as of November 2025.

SciSparc Ltd. as an Industry Innovator

SciSparc Ltd. is positioning itself not just as another biotech firm, but as a key innovator in the specialized field of cannabinoid pharmaceuticals and central nervous system (CNS) disorders. They are not a large-cap leader, but they are a trend-aware player making strategic moves to gain a leadership position in niche areas.

The company's focus on using cannabinoid-based therapies for complex conditions like Tourette syndrome, Alzheimer's disease and agitation, and autism spectrum disorder puts them at the forefront of a growing, high-potential market segment. Their recent collaboration with Clearmind Medicine Inc. has been particularly fruitful, leading to the filing of a new Israeli patent application in November 2025 for a combination therapy targeting depression. This is a smart move, expanding their intellectual property portfolio beyond their core pipeline into a major global health issue that affects about 332 million people worldwide.

They are also targeting quantum-powered 3D protein modeling technology to revolutionize AI drug discovery, which shows a commitment to leveraging cutting-edge tools. This aggressive pursuit of new technology and intellectual property, rather than just incremental drug development, is why you should view SciSparc Ltd. as a company building a future leadership position in specialized CNS drug development. You need to look past the small sales numbers and focus on the value of the intellectual property they are accumulating.

SciSparc Ltd. (SPRC) Mission Statement

You're looking at a clinical-stage pharmaceutical company like SciSparc Ltd. (SPRC) and the core question is simple: where are they spending their limited capital, and what is the long-term payoff? The mission statement is the lens for that analysis. It's not just a marketing phrase; it's the operational blueprint that guides every dollar of Research and Development (R&D) spend and every strategic transaction, especially when the company reported a net loss of USD 9.33 million in the first half of 2025.

SciSparc's mission is to develop and commercialize innovative, cannabinoid-based therapies for debilitating Central Nervous System (CNS) disorders, creating significant value for patients and shareholders through rigorous science and strategic asset development. This mission is a clear roadmap that justifies their current cash burn and maps directly to three critical components we, as analysts, track: the scientific platform, the market focus, and the financial strategy.

You can dig deeper into the company's investor landscape and strategic positioning by reading Exploring SciSparc Ltd. (SPRC) Investor Profile: Who's Buying and Why?

Pillar 1: Scientific Innovation and Precision Medicine

The first core component of the mission is a commitment to advanced scientific platforms, specifically leveraging proprietary cannabinoid-based compounds. This isn't about selling a commodity; it's about creating a defensible intellectual property (IP) moat. The company's focus is on drug candidates that combine FDA-approved synthetic cannabinoids with its proprietary formulation, CannAmide™ (palmitoylethanolamide, or PEA), to improve efficacy and reduce side effects.

The evidence is in the pipeline and the IP portfolio. Honestly, the most telling sign of their commitment is the recent push into next-generation technology. In September 2025, SciSparc announced an initiative to leverage Quantum Computing-Enabled 3D Protein Modeling to revolutionize its Artificial Intelligence (AI) drug discovery process. That's a defintely clear signal they are prioritizing the how-the method of discovery-over simply chasing market trends.

• SCI-110: In a Phase IIb clinical trial for Tourette Syndrome.
• SCI-210: In a randomized, double-blind trial for Autism Spectrum Disorder.
• IP Portfolio: The collaboration with Clearmind Medicine Inc. has resulted in 13 patents filed across various therapeutic areas.

Pillar 2: Addressing Unmet Central Nervous System Needs

A mission is only as good as the market it serves. SciSparc's second pillar targets high-impact, underserved CNS disorders. This focus is a calculated risk/reward play: high development cost but massive potential market size if they succeed. Their pipeline targets conditions with significant global burdens and limited effective treatments.

For example, the majority-owned subsidiary, NeuroThera Labs Inc., in which SciSparc holds a controlling interest of approximately 75%, recently filed a patent application (November 20, 2025) for a new combination therapy targeting depression. This is a huge, unmet need: according to World Health Organization data from August 2025, major depressive disorder affects approximately 332 million people worldwide, representing an estimated 5.7% of adults globally. This strategic move aligns their R&D directly with a severe, widespread public health challenge, validating the why of their existence.

The completed Phase II clinical trial for SCI-110 in Alzheimer's disease and agitation also speaks to this focus. They are tackling complex, high-cost diseases where a first-in-class or best-in-class treatment could generate billions in revenue, offsetting the modest H1 2025 sales of USD 0.461 million from their existing nutraceutical business.

Pillar 3: Strategic Value Creation for Shareholders

For a clinical-stage company, the third mission component-creating shareholder value-is not about quarterly profit; it's about strategically managing and monetizing assets. This involves a clear plan for capital efficiency and growth. The recent corporate actions are the concrete proof of this pillar.

The most significant action in 2025 was the strategic spin-off. SciSparc is transferring its advanced pharmaceutical assets to Miza III Ventures Inc. (which will be renamed NeuroThera Labs Inc.) in exchange for a controlling equity stake. The value of the transferred assets was approximately US$11.6 million. Following the closing, SciSparc is expected to hold a controlling interest in the resulting entity, ranging from a minimum of approximately 75% to a maximum of approximately 84%. This move monetizes the R&D investment, separates the high-risk pharma assets into a new vehicle, and maximizes the value of the core IP for SciSparc shareholders.

Here's the quick math: by transferring assets valued at US$11.6 million into a new entity where they retain a 75%+ stake, they create a new, publicly traded vehicle for their drug portfolio, which is a classic way to unlock value for shareholders without a full sale. This action is critical, especially after the 1-for-21 reverse share split, effective July 3, 2025, which reduced the number of outstanding shares from over 11 million to approximately 534,600 shares to maintain Nasdaq listing compliance.

SciSparc Ltd. (SPRC) Vision Statement

You want to know what drives SciSparc Ltd. (SPRC) beyond the stock ticker, and that's smart. For a clinical-stage pharmaceutical company, the vision isn't just a poster on the wall; it's the pipeline. The core mission is clearly focused on developing novel, non-hallucinogenic treatments for central nervous system (CNS) disorders, which is a massive and defintely underserved market.

The company's vision breaks down into three actionable pillars: delivering innovative neuro-therapeutics, aggressively building a strategic intellectual property (IP) portfolio, and maintaining focused financial stewardship to fund the long-term drug development process. Here's the quick math: in the first half of 2025, the company reported sales of only $0.461 million, but the net loss hit $9.33 million, which tells you they are burning cash to fuel that vision. This is a pure R&D play.

Pioneering Non-Hallucinogenic Neuro-Therapeutics

SciSparc's primary mission is to translate its proprietary drug-development platform-which initially focused on cannabinoid-based treatments-into commercial products for high-need CNS conditions like Tourette Syndrome, Alzheimer's disease, and autism spectrum disorder. The vision is to be a leader in this niche, but with a critical focus: non-hallucinogenic compounds.

Their lead candidate for Alcohol Use Disorder (AUD), CMND-100, is a perfect example. The drug is currently in an FDA-approved Phase I/IIa clinical trial at Hadassah Medical Center. Initial results from the first cohort look promising, showing a favorable safety profile and good adherence, which is crucial for any addiction treatment. The goal here is to offer a safer, more accessible alternative to traditional addiction therapies.

• Focus on CNS disorders, not general medicine.
• Develop non-hallucinogenic, safer drug alternatives.
• Advance CMND-100 through clinical trials.

Strategic IP Expansion and Collaboration

A core value for SciSparc is aggressive innovation, which they execute through strategic partnerships and a relentless focus on intellectual property (IP). You can't build a pharma company without a deep IP moat, so they are constantly filing patents.

The most recent action, in November 2025, saw their majority-owned subsidiary, NeuroThera Labs Inc. (in which SciSparc holds a 75% controlling interest), file an Israeli patent application. This patent covers an innovative combination therapy for depression, partnering with Clearmind Medicine Inc. This collaboration has already resulted in a total of 13 patent applications, covering conditions from alcohol use disorder to obesity and depression. The market is huge: World Health Organization data from August 2025 shows approximately 332 million people worldwide are living with depression. That's a clear opportunity.

Focused Financial Stewardship in R&D

The company's financial structure reflects its mission: every dollar is a bet on future success. The core value here is stewardship, meaning they must be hyper-efficient with their capital to survive the long, costly drug-development cycle. For the half-year ended June 30, 2025, the basic loss per share from continuing operations was $17.92, which underscores the high cost of clinical trials and R&D. While the company's total assets were $7.59 million at the end of 2023, down from $10.46 million in 2022, the current focus is on maximizing the impact of their existing capital and partnerships.

What this estimate hides is the potential value of the 13 patents filed; those are intangible assets that don't show up on the income statement today but could be worth billions if a single drug hits Phase III and gets approval. This is why you look past the current revenue number and focus on the pipeline and IP portfolio. You can read more about the company's financial journey and strategy at SciSparc Ltd. (SPRC): History, Ownership, Mission, How It Works & Makes Money.

SciSparc Ltd. (SPRC) Core Values

You're looking for the operating principles that drive a clinical-stage pharmaceutical company like SciSparc Ltd. (SPRC), especially one navigating the complex cannabinoid-based therapy space. Honestly, the core values are the bedrock for understanding their strategy and risk profile. We can map their actions in 2025 directly to three core pillars: Pioneering Innovation, Patient-Centric Development, and Strategic Collaboration. This approach helps simplify what is defintely a high-risk, high-reward sector.

For a deeper dive into the company's background, you can check out SciSparc Ltd. (SPRC): History, Ownership, Mission, How It Works & Makes Money.

Pioneering Innovation

Innovation is the lifeblood of any specialty pharmaceutical firm, and for SciSparc Ltd., it means constantly pushing beyond conventional cannabinoid research. This value is the commitment to developing truly novel solutions for unmet medical needs, especially in the central nervous system (CNS) space. The market values intellectual property (IP) and pipeline potential more than current sales for a company of this stage; the latest reported sales for the half year ended June 30, 2025, were only $0.461 million, so the focus must remain on future-proofing the technology.

Here's the quick math on their commitment to new tech:

• Launched a September 2025 initiative to develop quantum-powered 3D protein modeling for AI drug discovery [cite: 2 in previous step, 7 in previous step].
• This move is a clear signal that they are investing in next-generation technology to refine quantum algorithms for protein folding and protein-ligand interactions [cite: 2 in previous step].
• They are building a dedicated research team and a wholly owned Israeli subsidiary for this program [cite: 2 in previous step].

They are trying to leapfrog the competition with AI. That's a pure R&D bet.

Patient-Centric Development

The core mission of SciSparc Ltd. is to treat disorders and rare diseases of the central nervous system, which is a direct reflection of their Patient-Centric Development value. Everything hinges on getting a drug from the lab to the patient, and this value guides their clinical pipeline decisions. Their drug development programs are focused on high-impact, difficult-to-treat conditions, which is where the greatest patient need-and potential revenue-lies.

The financial results for the nine months ended September 30, 2025, showed a net income of $1.46 million, a significant metric that supports continued investment in these costly clinical trials.

• SCI-110: Targeting Tourette syndrome and Alzheimer's disease with agitation.
• SCI-210: Focused on treating autism spectrum disorder and status epilepticus.
• CannAmide: A solution for anti-inflammatory and chronic pain.

They have to manage the high volatility of their share price-which saw a weekly volatility increase from 37% to 49% over the past year-while keeping the patient focus front and center [cite: 9 in previous step].

Strategic Collaboration & Growth

As a smaller clinical-stage firm with a market capitalization of only $3.89 million as of November 2025, SciSparc Ltd. must use partnerships and strategic transactions to expand its reach and manage risk. This value of Strategic Collaboration is about maximizing the value of their intellectual property (IP) and clinical assets through smart business moves, not just internal R&D.

The second half of 2025 was defined by these strategic actions:

• Asset Transfer: Closed a transaction on October 22, 2025, to transfer its advanced clinical-stage pharmaceutical portfolio to Neurothera Labs Inc., a company in which SciSparc Ltd. holds approximately 75% controlling interest [cite: 2 in previous step].
• Valuation: This deal valued the Target Assets at approximately US$11.6 million, which is a huge number relative to the company's current market cap [cite: 2 in previous step].
• Joint IP: Filed an Israeli patent application on November 20, 2025, in collaboration with Clearmind Medicine Inc. for a novel non-hallucinogenic neuroplastogen treatment for depression [cite: 2 in previous step].

They are using M&A and partnerships to get their drugs closer to commercialization. This is how a small company survives in a big pharma world.